HSBC has initiated coverage on Repligen Corp (RGEN) with a Buy rating, marking its first assessment of the company. This decision underscores the firm's evaluation of Repligen's investment potential based on its research into the life sciences sector, where the company operates.
Headquartered in Waltham, Massachusetts, Repligen is a global leader in bioprocessing technologies and solutions for the production of biological drugs. The company employs 1,778 full-time staff and focuses on key areas such as Filtration and Fluid Management, Chromatography, Process Analytics, and Proteins. Its filtration products support both process development and commercial production, while its chromatography franchise includes essential tools for downstream purification and quality control.
As of September 30, 2025, Repligen's shares are priced at $162.19. The company boasts a market capitalization of $8.9 billion and a trailing twelve-month price-to-earnings ratio of 5,146.17, with earnings per share at $0.03. Upcoming earnings reports are scheduled for July 27, 2026, with an estimated EPS of $0.50 and revenue of $207.6 million, and April 27, 2026, expecting an EPS of $0.46 and revenue of $195.1 million.
Analyst ratings, such as this new Buy designation from HSBC, provide insights based on financial models and research. However, these ratings should be considered alongside company fundamentals, competitive positioning, and broader industry trends, as they can evolve with new information. Currently, the analyst consensus for Repligen includes 7 Strong Buy, 15 Buy, and 6 Hold ratings, reflecting a generally favorable view among analysts.
The update highlights HSBC's confidence in Repligen's growth prospects within the life sciences tools and services industry, which remains a dynamic sector amid ongoing advancements in bioprocessing technologies.